GlassScriptPhysician profile
Eric A Carlon
NPI 1013525294
$2,387.53
in general payments reported to CMS, 2019-2025
11 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2023: $1,544 · 2024: $57.06 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,175 · Food and Beverage: $1,000 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,175.00 |
| Food and Beverage | $999.78 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,181.88 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $590.75 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $179.95 | 2022-2023 | Ingrezza |
| Alpha Cognition USA, INC. | $143.94 | 2025 | Zunveyl |
| Alkermes, INC. | $98.28 | 2023-2024 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $68.34 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $33.59 | 2025 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $24.68 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $24.44 | 2022 | |
| Noven Therapeutics, LLC | $23.80 | 2022 | |
| Lundbeck LLC | $17.88 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Carlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.